Skip to content

CRISPR-Edited Fibroblasts

User-supplied, gene-edited primary fibroblasts

High editing efficiency with reliable post-editing functionality. Work with our team to edit your primary cell type of interest.

Using other primary cell lines? Reach out to us about custom projects!
Contact Us
Overview

Your cell lines, our confident knockouts

Reliable Editing: >80% KO editing efficiency with EditCo’s XDel guide design

Rapid Results: Edited cells in 4 weeks or faster from cell line receipt

High-throughput: Streamline screening with our fibroblast editing at library scales

Fit to Your Needs: A flexible CRISPR platform enables efficient editing of customer-supplied cells

Fibroblast

Cell Pools Clones Timeline

Primary Fibroblast KO Pools are made-to-order knockouts with editing efficiencies >80% generated in 4 weeks or faster from receiving IDEXX approved cells. EditCo consistently achieves >90% editing efficiency, creating cell pools that are functionally similar to a clone. As primary cell clones are biologically difficult to produce, EditCo’s high editing efficiency provides a unique approach to generating cell populations of interest.

Whether you are leveraging CRISPR for validating targets for drug discovery or modeling a biological process for the investigation of a novel gene of interest, failed experiments lead to a loss of time and resources. EditCo’s Primary Fibroblast KO Pools are the solution for obtaining quick and reliable functional data while reducing the risk for false negatives in your critical assays.

Easily Scalable Platform

Deliverables

What We Provide

EditCo’s proprietary editing protocols deliver high-efficiency edits at scale. Our Knockout Fibroblast Cells, powered by XDel Technology, provide researchers with the confidence and reproducibility they need for guaranteed CRISPR knockouts.

KO Pool Stability

Example editing efficiency of a large library screen: 90% of targets with greater than 80% editing efficiency across 64 total targets in human large intestine primary fibroblasts.

 

Edited Fibroblast Cell Options

Single-edit Knockout Cell Pools

  • 2 vials of 1M edited cell pools (1M/vial)
  • 2 vials of control mock transfected cell pools
  • Sequence of synthetic sgRNAs used
  • Primer sequences used for PCR and NGS sequencing
  • NGS sequencing analysis reports
  • Comprehensive QC report including Mycoplasma tests and passage number

Knockout Cell Screening Libraries

  • 2 vials of each pool with 20k cells per vial in arrayed format
  • 5 control pools per rack: 2 mock WT, 2 multi-guide KO, 1 single-guide KO
  • Sequence of synthetic sgRNAs used
  • Primer sequences used for PCR and Sanger sequencing
  • Sanger sequencing analysis reports
  • Comprehensive QC report including Mycoplasma tests and passage number

For Additional Information on our Primary Fibroblast offering, download our flyer below.

Downstream Applications and Partnerships

EditCo’s made-to-order knockout fibroblast services enable you to further research in CNS disorders, wound healing, cystic fibrosis, autoimmunity, cancer, or other disease areas where fibroblasts have been implicated. Furthermore, EditCo’s extensive Discovery Partners Ecosystem creates a seamless workflow from EditCo’s CRISPR engineered cells to phenotypic data, providing researchers with a faster, more efficient, and more reliable way to drive their discoveries forward.

Resources

Flyer
Research-ready, CRISPR-edited Fibroblasts
Learn more about our made-to-order, high-efficiency edited primary human fibroblast pools.
Download Now
Flyer
Industrialized CRISPR Cells: CRISPR Done for You
EditCo's next-generation engineered cells provide researchers with access to the benefits of CRISPR. You no longer need to invest significant time and money to learn and optimize methods.
Learn More
flyer
Knockout Primary Immune Cell Pools
Edited-to-order Knockout CD4+ T-cells guarantee high knockout efficiency while retaining high cell viability and post-editing functionality.
Learn More
Poster
Rapid and Efficient Genome Editing for Human Primary T-Cells
EditCo can quickly provide functional, stable, made-to-order edited T-cells from a variety of prevalidated donors using our genome engineering platform. Presented at Immuno-Oncology 2024.
Learn More
Peer-reviewed Paper
Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells
Learn how we're carving a path for potential "off-the-shelf" CAR-T therapies in collaboration with the Saha lab at the University of Wisconsin - Madison.
Learn More
EditCo's Automated CRISPR Platform

Integrating our core CRISPR expertise, high-quality reagents, and automated processes, we deliver the best edited cell-based models at any scale.

CRISPR Engineered Cells Enable Variant Disease Modeling
Icon_Pools_Trans
Leveraging a sophisticated infrastructure with integration between bioinformatics, software, and automated platforms
Learn More
Icon_TCell_Trans
Automating biology and synergistic disciplines for streamlined cell editing and cell culture workflows
Learn More
Icon_iPSC_Trans
Delivering experiment-ready edited cells for your next discoveries through a robust and cohesive ecosystem
Learn More
Testimonials 1

Testimonials consectitur amet sed

Lorem Button Text
Congue fermentum eros leo commodo. Integer vitae vitae ac amet. Vitae sed lectus vel lacus adipiscing nulla facilisis mauris porttitor. Viverra elementum odio vitae id.
AI_Webinar_a-1
Albert Rose, Ph. D.
Principal Investigator, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
Viverra aliquam volutpat interdum quisque vel mattis. Malesuada aliquam egestas pharetra a tempus ullamcorper egestas.
placeholder-56x56
Amanda Peyton, Ph. D.
Principal Investigator, Boston Children's Hospital, Dana-Farber Cancer Institute
Nibh luctus pulvinar sagittis faucibus commodo vitae purus. Ullamcorper dictum.
placeholder-56x56
Joseph James, Ph. D.
Principal Investigator, Boston Children's Hospital
Congue fermentum eros leo commodo. Integer vitae vitae ac amet. Vitae sed lectus vel lacus adipiscing nulla facilisis mauris porttitor. Viverra elementum odio vitae id.
placeholder-56x56
Albert Rose, Ph. D.
Principal Investigator, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
Congue fermentum eros leo commodo. Integer vitae vitae ac amet. Vitae sed lectus vel lacus adipiscing nulla facilisis mauris porttitor. Viverra elementum odio vitae id.
placeholder-56x56
Albert Rose, Ph. D.
Principal Investigator, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
Congue fermentum eros leo commodo. Integer vitae vitae ac amet. Vitae sed lectus vel lacus adipiscing nulla facilisis mauris porttitor. Viverra elementum odio vitae id.
placeholder-56x56
Albert Rose, Ph. D.
Principal Investigator, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
Lorem Button Text

Lectus Pluristyx eu vel leo lectus mi. Viverra cursus neque eget proin.

Pellentesque nec tempus ultrices purus amet adipiscing aliquam. Posuere imperdiet adipiscing non blandit non. Sed eros vel sodales magna sem tincidunt orci risus. Molestie hendrerit cursus faucibus ac neque eget turpis. Arcu leo risus iaculis mi. Tortor bibendum sed cras pretium leo.

0+

Edits Performed

0+

Edits Performed

0+

Edits Performed
Lorem Overline

Lorem Ipsum Dolor Heading

Etiam sollicitudin, ipsum eu pulvinar rutrum, tellus ipsum laoreet sapien, quis venenatis ante odio sit amet eros. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum. Maecenas nec odio et ante tincidunt tempus. Donec elit libero, sodales nec, volutpat a, suscipit non, turpis. Quisque id mi.

Lorem Button Text
Lorem Overline

Resources aliquam procte

Lorem Button Text
placeholder-280x160
Lorem overline
Ultrices nullam dictumst erat molestie massa a amet pulvinar bibendum lacus.
Tortor consectetur viverra malesuada dignissim duis quis. Morbi purus in velit lacus diam odio sed. Sed nisl arcu amet ut.
Read More
placeholder-280x160
Lorem overline
Ultrices nullam dictumst erat molestie massa a amet pulvinar bibendum lacus.
Tortor consectetur viverra malesuada dignissim duis quis. Morbi purus in velit lacus diam odio sed. Sed nisl arcu amet ut.
Read More
placeholder-280x160
Lorem overline
Ultrices nullam dictumst erat molestie massa a amet pulvinar bibendum lacus.
Tortor consectetur viverra malesuada dignissim duis quis. Morbi purus in velit lacus diam odio sed. Sed nisl arcu amet ut.
Read More
placeholder-280x160
Lorem overline
Ultrices nullam dictumst erat molestie massa a amet pulvinar bibendum lacus.
Tortor consectetur viverra malesuada dignissim duis quis. Morbi purus in velit lacus diam odio sed. Sed nisl arcu amet ut.
Read More
placeholder-280x160
Lorem overline
Ultrices nullam dictumst erat molestie massa a amet pulvinar bibendum lacus.
Tortor consectetur viverra malesuada dignissim duis quis. Morbi purus in velit lacus diam odio sed. Sed nisl arcu amet ut.
Read More
placeholder-280x160
Lorem overline
Ultrices nullam dictumst erat molestie massa a amet pulvinar bibendum lacus.
Tortor consectetur viverra malesuada dignissim duis quis. Morbi purus in velit lacus diam odio sed. Sed nisl arcu amet ut.
Read More
Lorem Button Text

Reach out to our experts to find out what EditCo can do for you